Dermavant Sciences, Inc.
$9.7M 73,486 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. reported $9,721,995.70 across General Payments, Research, and Ownership to 61,253 physicians and teaching hospitals across 61,817 transactions.
- $9.7M
- All-tracks total
- 61,817
- Transactions
- 61,253
- Recipients
- +$1.2M
- General Payments vs PY2023
Supernus Pharmaceuticals, Inc. reported $9,721,995.70 across all CMS Open Payments tracks (General + Research + Ownership) to 61,253 physicians and teaching hospitals in Program Year 2024 - ranking #178 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $4,374,339.01, averaging $158.72 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer supernus-pharmaceuticals-inc Supernus Pharmaceuticals, Inc.
$9.7M · #178/1,925 · 0.1% industry · PY2024
- TOT $9.7M
- RANK #178
- SHARE 0.1%
- TXN 61,817
- RCP 61,253
- CAT 6
- GEN $4.4M
- ΔGEN +$1.2M
- TOP1 2.3%
- PY 2024
Volume peers
Nearest volume peer: Dermavant Sciences, Inc. ($9.7M)
Supernus Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Supernus Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $1.2M (+35.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SUPERNUS PHARMACEUTICALS, INC.PY2023: SUPERNUS PHARMACEUTICALS, INC.PY2024: Supernus Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $3,220,676.77
- PY2024
- $4,374,339.01
What the Data Shows for Supernus Pharmaceuticals, Inc.
In Program Year 2024, Supernus Pharmaceuticals, Inc. reported $9,721,995.70 in payments to 61,253 physicians and teaching hospitals across 61,817 individual transactions, an average of $157.27 per transaction and $158.72 per recipient. That total places Supernus Pharmaceuticals, Inc. at rank #178 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.
"Food and Beverage" leads the 6-category general-payment breakdown below at $1.8M (41.3% of General Payments, 58,524 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 6 types of general payments, Supernus Pharmaceuticals, Inc.'s largest category was "Food and Beverage" at $1.8M - 41.3% of General Payments.
Supernus Pharmaceuticals, Inc. reports 6 general-payment categories - the top three are Food and Beverage (41.3%), Compensation for Services Other Than Consulting (38.1%), and Honoraria (13.5%). The remaining 3 categories make up 7.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Supernus Pharmaceuticals, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.8M | 58,524 | 41.3% |
| Compensation for Services Other Than Consulting | $1.7M | 914 | 38.1% |
| Honoraria | $591.8K | 204 | 13.5% |
| Travel and Lodging | $307.5K | 1,598 | 7.0% |
| Consulting Fee | $2.0K | 4 | 0.0% |
| Education | $56.87 | 9 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $355,842.56 (8.1%) of $4,374,339.01 in this company's General Payments records across 14,938 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Supernus Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Ann Childress
$99,543.04 across 130 reported transactions
- 2
Birgit Amann
$87,284.10 across 123 reported transactions
- 3
Andrew Cutler
$63,343.80 across 76 reported transactions
- 4
Alice Mao
$53,075.28 across 68 reported transactions
- 5
Frank Lopez
$52,596.34 across 72 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Supernus Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Supernus Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Supernus Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Route 92 Medical, Inc.
$9.7M 774 recipients
Compare payment profiles
EyePoint Pharmaceuticals US, Inc.
$9.7M 748 recipients
Compare payment profiles
H. Lundbeck A S
$9.8M 303 recipients
Compare payment profiles
W. L. Gore & Associates, Inc.
$9.5M 25,860 recipients
Compare payment profiles
Applied Medical Research, Inc
$10.0M 0 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.